CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
详细信息 查看全文
- 作者：Colin W. Steele1 ; Saadia A. Karim1 ; Joshua D.G. Leach1 ; Peter Bailey2 ; Rosanna Upstill-Goddard2 ; Loveena Rishi2 ; Mona Foth1 ; Sheila Bryson1 ; Karen McDaid3 ; Zena Wilson3 ; Catherine Eberlein3 ; Juliana B. Candido4 ; Mairi Clarke5 ; Colin Nixon1 ; John Connelly1 ; Nigel Jamieson6 ; C. Ross Carter6 ; Frances Balkwill4 ; David K. Chang2 ; T.R. Jeffry Evans1 ; 2 ; Douglas Strathdee1 ; Andrew V. Biankin2 ; Robert J.B. Nibbs5 ; Simon T. Barry3 ; Owen J. Sansom1 ; 2 ; 7 ; o.sansom@beatson.gla.ac.uk" class="auth_mail" title="E-mail the corresponding author ; Jennifer P. Morton1 ; 2 ; 7
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：13 June 2016
- 年：2016
- 卷：29
- 期：6
- 页码：832-845
- 全文大小：7126 K
文摘
- •
CXCR2 signaling is upregulated in myeloid cells in human pancreatic cancer
- •
Cxcr2 loss reduces metastasis and inhibition prolongs tumor-free survival in mice
- •
Neutrophils/MDSCs play a key role in the establishment of the metastatic niche
- •
CXCR2 inhibition enhances T cell entry and confers sensitivity to anti-PD1 therapy